Latest Conference Coverage

Multi-Modal Wristband Sensors May Predict Seizures

The initial study results may provide the basis for future evaluation as a step towards patient empowerment and objective epilepsy diagnostics for broad application.

Vineet Punia, MD, MS: Phase 4 ELEVATE Trial of Perampanel for Partial Onset Seizures

The neurologist from Cleveland Clinic discussed initial data from Study 410 and patient compliance rates with perampanel treatment.

Christian Meisel, MD, PhD: Forecasting Seizures Using Multi-Modal Wristband Sensors

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health detailed his study from AES 2020 on using wristband sensor data to forecast seizures.

Reduction in Concomitant Antiseizure Medications Improves Cenobamate Retention Rates

High retention rates and number of patients remaining seizure-free for prolonged periods indicated the efficacy of cenobamate in treating focal seizures.

Fenfluramine Demonstrates Efficacy in Lennox-Gastaut Syndrome in Phase 3 Results

Fenfluramine was particularly effective in reducing generalized tonic-clonic seizure frequency in patients with Lennox-Gastaut syndrome, with a push for regulatory submission in the future.

Perampanel Reports High Compliance and Good Tolerance in Phase 4

High compliance rates and well-tolerance of perampanel indicate its efficacy as a treatment for partial onset seizures.

Benjamin M. Segal, MD: Escalation Versus Induction in MS

The chair of the department of neurology at The Ohio State University spoke to the ongoing conversation in MS about how aggressive to be with treatment early on.

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

CLARITY Extension Trial: Disability Improvement With Cladribine

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

Benjamin M. Segal, MD: The Multiple Sclerosis Prodrome

The chair of the department of neurology at The Ohio State University discussed the idea of the multiple sclerosis prodrome, presented in a plenary address at the MS Virtual 2020 meeting.

Benjamin M. Segal, MD: MS Virtual 2020 Highlights

The chair of the department of neurology at The Ohio State University discussed some of the main themes and takeaways from the MS Virtual 2020 meeting.

Rajesh Pahwa, MD: Understanding Levodopa-Carbidopa Treatment Impact

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center provided insight on the lapses in levodopa-carbidopa treatment and what potential changes could come in the future.

Rajesh Pahwa, MD: Underutilization of Levodopa-Carbidopa Intestinal Gel

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center shared the reasons why LCIG is underused in clinical care.

Joaquim Ferreira, MD, PhD: The Magnitude of Effect for Opicapone in Parkinson Disease

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

Rajesh Pahwa, MD: Advantages of Levodopa-Carbidopa Intestinal Gel

The director of the Parkinson’s Foundation Center for Excellence at University of Kansas Medical Center detailed the pros and cons of levodopa-carbidopa intestinal gel.

Satralizumab Benefits Relapse Risk Across NMOSD Treatment Spectrum

The medical director manager of neuroscience at Genentech offered her perspective on the mountain of data presented at MS Virtual 2020 on the recently approved NMOSD treatment.

Ponesimod Shows Safe Cardiac Profile in MS

Researchers concluded that uptitration of ponesimod was not associated with clinically significant bradyarrhythmia events; none were serious or lead to discontinuation.